Li Y-R*#, Zhu Y*, Shen X, Chen Y, and Yang L#. (*Co-first authors; #Co-corresponding authors). Allogeneic immunotherapy. Nat Rev Bioeng (2026). https://doi.org/10.1038/s44222-026-00468-w. Online publication ahead of print. 2026 August 5. [Nature Reviews Bioengineering PDF]
Li Y-R*#, Zhu Y*, Li Z, Shen X, Li S, Chen Y, Lyu Z, Huang J, Ma NY, Zhang C, Zhao AS, Tian Y, Zhou XJ, and Yang L#. (*Co-first authors; #Co-corresponding authors). Universal Rejuvenated Hematopoietic Stem and Progenitor Cell-Engineered CAR-Armored Natural Killer T Cells for Malignant Pleural Mesothelioma. Research. 2026 June 11;9:1310. DOI: 10.34133/research.1310. [Research PDF]
Li Y-R#, Chen Y, and Yang L#. (#Co-corresponding authors). Exploring CAR cell therapies beyond CAR-T for myeloid malignancies. J Biomed Sci. 2026 June 4;33(1):60. doi: 10.1186/s12929-026-01265-8. [Journal of Biomedical Science PDF]
Citradewi Soemardy*, Yan-Ruide Li*, Yichen Zhu*, Xinyuan Shen, Lili Yang# and Dino Di Carlo#. (*Co-first authors; #Co-corresponding authors). Universal Nanovial Screening Enabales Functional Discovery of Metabolite-Reactive T-Cell Receptors for Cancer Therapy. ACS Nano. 2026 Apr 28;20(16):12405-12415. doi: 10.1021/acsnano.5c22721. Epub 2026 Apr 16. [ACS Nano PDF]
Shen X, Li Y-R# and Yang L#. (Co-corresponding authors). Igniting CAR-NKT cells with IL-18. Mol Ther. 2026 Apr 1;34(4):1882-1883. doi: 10.1016/j.ymthe.2026.02.039. Epub 2026 Mar 7. [Molecular Therapy PDF]
Li Y-R, Shen X, Chen Y, Zhu Y, Huang J, Oliai C, and Yang L. Synergizing hypomethylating agents with off-the-shelf CD70-targeted chimeric antigen receptor-engineered natural killer T cells for the treatment of acute myeloid leukemia. Leukemia. 2026 Mar 26. doi: 10.1038/s41375-026-02930-5. Online ahead of print. [Leukemia PDF][Clear Sky Science PDF]
Kang E*, Elsten-Brown J*, Wang Y-C*, Lam A, Sanchez E, Wen R, Wang T, Chiang J, Scarborough Q, Li Y-R, Zhu Y, Huang J, Williams M, Eckl S, Li B# and Yang L#. (Co-first authors; Co-corresponding authors). Creatine uptake promotes dendritic cell activation and enhances antitumor immunity. iScience. 2026 Apr 17;29(4):115436. 10.1016/j.isci.2026.115436. Epub 2026 Mar 21. [iScience PDF][ScienceDaily PDF]
Li Y-R# and Yang L#. (Co-corresponding authors). Protocol to generate human stem cell-derived CD70-directed allogeneic CAR-NKT cells for treating renal cell carcinoma. STAR Protoc. 2026 Mar 20;7(1):104340. doi: 10.1016/j.xpro.2025.104340. Epub 2026 Jan 13. [STAR Protocols PDF]
Li Y-R*, Nan H*, Liu Z*, Fang Y, Zhu Y, Lyu Z, Shao Z, Zhu E, Zhang B, Yang Y, Shen X, Chen Y, Hsiai T, Yang L# and Li S#. (*Co-first authors; #Co-corresponding authors). Engineering an in vivo charging station for CAR-redirected invariant natural killer T cells to enhance cancer therapy. Nat Biomed Eng. 2026 Mar 17. doi: 10.1038/s41551-026-01629-3. Online ahead of print. [Nature Biomedical Engineering PDF][UCLA Samueli Newsroom PDF][UCLA BSCRC News PDF]
Li Y-R*, Zhu Y*, Halladay T*, Shen X, Yang Y, Li Z, Zhu E, Chen Y, Huang J, and Yang L. (*Co-first authors). Engineering optimal CAR constructs for allogeneic mesothelin-directed CAR-NKT cells in solid tumor immunotherapy. Blood ICT. 2026 March;2(1):100025. doi: 10.1016/j.bict.2025.100025. Epub 2026 Jan 21. [Blood Immunology & Cellular Therapy PDF]
Li Y-R*#, Li M*, Chen Y*, Leng H, Zhu Y, Shen X, Croll D, Zhu E, Huang J, Wang Y-C, Krall AS, Christofk HR, Lusis AJ, and Yang L#. (*Co-first authors; #Co-corresponding authors). Spatiotemporal profiling reveals distinct dynamics and checkpoint regulations of CAR-T and CAR-NKT cells against solid tumors. Signal Transduct Target Ther. 2026 Mar 12;11(1):92. doi: 10.1038/s41392-026-02602-x. [Signal Transduction and Targeted Therapy PDF][Clear Sky Science PDF]
Li Y-R#, Chen Y, and Yang L#. (Co-corresponding authors). Stealth designs to overcome allorejection in engineered cell therapy. Trends Immunol. 2026 Mar 11:S1471-4906(26)00039-6. doi: 10.1016/j.it.2026.02.008. Online ahead of print. [Trend in Immunology PDF]
Li Y-R#, Chen Y, and Yang L#. (#Co-corresponding authors). Redefining multiple sclerosis with CAR-T cell therapy. Mol Ther. 2026 Mar 4;34(3):1326-1339. doi: 10.1016/j.ymthe.2025.12.022. Epub 2025 Dec 11.[Molecular Therapy PDF]
Liu Z*, Li Y-R*, Yang Y*, Shen X, Zhu E, Nan H, Wang S, Lin J, Yang L# and Li S#. (*Co-first authors; #Co-corresponding authors). Engineering biomaterials for next-generation cancer immunotherapy: From cell manufacturing to in vivo modulation. Cell Biomater. 2026 May 19;2:100380. doi: 10.1016/j.celbio.2026.100380. Epub 2026 Mar 4. [Cell Biomaterials PDF]
Li Y-R*, DiBernardo GA*, Chen Y, Shen X, Hon R, Ruegg LE, Huang J, Neal A, Moatamed NA, Memarzadeh S#, and Yang L#. (*Co-first authors; #Co-corresponding authors). Stem cell engineering for the generation of allogeneic CAR-directed natural killer T cells targeting endometrial carcinoma. Exp Hematol Oncol. 2026 Jan 29;15(1):14. doi: 10.1186/s40164-026-00746-8. [Experimental Hematology & Oncology PDF][UCLA Newsroom PDF][UCLA Health News PDF]
Li Y-R# and Yang L#. (#Co-corresponding authors). Autologous, allogeneic, in vivo CAR for autoimmune diseases. Trends Pharmacol Sci. 2026 Jan;47(1):11-14. doi: 10.1016/j.tips.2025.11.001. Epub 2025 Nov 25. [Trends in Pharmacological Sciences PDF]
Chen Y, Fang Y, Lyu Z, Tian Y, Niu S, Li Y-R# and Yang L#. (#Co-corresponding authors). Microbiome modulation of tumorigenesis and immune responses. J Biomed Sci. 2026 33:4. doi.org/10.1186/s12929-025-01208-9. [Journal of Biomedical Sciences PDF]
Yang L, Ribas A & Witte ON. David Baltimore (1938-2025): His west coast voyage and his vision of a Los Angeles Bio-Hub. Nat. Biotechnol. 2025 Dec 8. http://doi.org/10.1038/s41587-025-02957-6. [Nature Biotechnology PDF][UCLA MIMG][UCLA BSCRC][X.parkerici]
Li Y-R#, Zhu Y, and Yang L#. (#Co-corresponding authors). Clinical technology advances driving in vivo CAR therapy. Trends Biotechnol. 2025 Nov 21:S0167-7799(25)00460-3. doi: 10.1016/j.tibtech.2025.11.006. Online ahead of print. [Trends in Biotechnology PDF]
Li Y-R, Shen X, Zhu E, Li Z, Huang J, Le T, Tran C, Radu C.G., and Yang L. Targeting orthotopic and metastatic pancreatic cancer with allogeneic stem cell-engineered mesothelin-redirected CAR-NKT cells. Proc Natl Acad Sci U S A. 2025 Nov 25;122(47):e2517786122. doi: 10.1073/pnas.2517786122. Epub 2025 Nov 21. [PNAS PDF][UCLA News PDF][Fox News PDF][Yahoo! News PDF]
Li Y-R# and Yang L#. (#Co-corresponding authors). From bench to body: In vivo CAR engineering in the clinic. Cell Rep Med. 2025 Nov18;6(11):102337. doi: 10.1016/j.xcrm.2025.102337. [Cell Reports Medicine PDF]
Chen Y*, Niu S*, Li Y-R# and Yang L#. (*Co-first authors; #Co-corresponding authors). Innovative gene engineering strategies to address tumor antigen escape in cell therapy. J Transl Med. 2025 Nov 5;23(1):1227. doi: 10.1186/s12967-025-07259-8. [Journal of Translational Medicine PDF]
Li Y-R, Shen X, Zhu Y, Li Z, Hon R, Tian Y, Huang J, Zhao A. S., Ma N. Y., zhang C, Lin D, Sargsyan K, Yuan Y, and Yang L. Targeting Triple-negative breast cancer using cord-blood CD34+ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity. J Hematol Oncol. 2025 October 13;18(1):86. doi: 10.1186/s13045-025-01736-9. [Journal of Hematology & Oncology PDF][UCLA News PDF][UCLA Health News PDF][Public Now PDF]
Liu Z*, Li Y-R*, Yang Y, Zhu E, Nan H, Yan Y, Zhang B, Chen G, Pedroncelli N, Lyu Z, Lin J, Soto J, Yang L# and Li S#. (*Co-first authors; #Co-corresponding authors). Manufacturing synthetic viscoelastic antigen-presenting cells for immunotherapy. Nat Protoc. 2025 October 9. doi.org/10.1038/s41596-025-01265-2. Online ahead of print. [Nature Protocols PDF]
Lyu Z, Li Y-R# and Yang L#. (#Co-corresponding authors). Protocol for assessing pharmacodynamics of human CAR-NKT cells in humanized mouse models using bioluminescence imaging. STAR Protoc. 2025 Sep 19;6(3):103957. doi: 10.1016/j.xpro.2025.103957. Epub 2025 Jul 19. [STAR Protocols PDF]
Li Y-R#, Zhu Y, Li Z, Shen X, Halladay T, Tse C, Tian Y, Huang J, Zhao AS, Ma NY, Zhang C, Nathanson DA, Prins RM, and Yang L#. (#Co-corresponding authors). Allogeneic stem cell-engineered EGFRvIII-specific CAR-NKT cells for treating glioblastoma with enhanced efficacy and safety. Mol Ther. 2025 September 12:S1525-0016(25)00754-3. doi: 10.1016/j.ymthe.2025.09.026. Online ahead of print. [Molecular Therapy PDF][Molecular Therapy Commentary PDF]
Li Y-R*, Hu J*, Li Z, Zhu E, Chen Y, Halladay T, Shen X, Fang Y, Zhu Y, Lyu Z, Tian Y, Huang J, Zhao AS, Ma NY, Zhang C, Xie Y, Zhang H, Hsiai T, Chin AI#, Wu L#, and Yang L#. (*Co-first authors; #Co-corresponding authors). Multimodal targeting of metastatic renal cell carcinoma via CD70-directed allogeneic CAR-NKT cells. Cell Rep Med. 2025 September 16. doi:10.1016/j.xcrm.2025.102321. 2025 August 29, online ahead of print. [Cell Reports Medicine PDF][UCLA Health PDF][UCLA BSCRC PDF][Today’s Clinical Lab PDF][MedPath PDF][Lab Manager PDF][Bioengineer PDF][Genetic Engineering & Biotechnology News PDF]
Li Y-R, Li Z, Zhu Y, Li M, Chen Y, Lee D, Ochoa CJ, Singh T, DiBernardo G, Guo W, Li S, Zhou Y, Yu Y, Kramer A, Wilson M, Zhou K, Dunn ZS, Fang Y, Yu J, Kim YJ, Huang J, Shen X, Wang Y-C, Hon R, Basso T, Chen E, Zhu E, Lin S, Neal A, Moatamed NA, Oh SS, Sadeghi S, Pan C, Wang A, Lusis AJ, Zhou XJ, Zhou JJ, Pellegrini M, Wang P, Memarzadeh S# and Yang L#. (#Co-corresponding authors). Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells. Med. 2025 Aug 12. doi:10.1016/j.medj.2025.100804. Online ahead of print. [Med PDF][UCLA Newsroom PDF][UCLA Health PDF][UCLA BSCRC PDF][UCLA Life Sciences PDF][Instagram PDF]
Zhu E, Zhang Y, Zhao P, Cho JM, Wang Z, Li Y-R, Wang J, Margolis S, Wang S, Yang L, Chu A, Zhang Y, Gao L, and Hsiai TK. Refractive index-corrected light-sheet microscopy for macro-view cardiovascular imaging. Adv Sci. 2025 Jul 13:e03684. doi: 10.1002/advs.202503684. Online ahead of print. [Advanced Science PDF]
Li Y-R#, Zhu Y, and Yang L#. (#Co-corresponding authors). IL-18 revives dysfunctional CAR-T cells. Trends Cancer. 2025 Jul 7:S2405-8033(25)00151-7. doi: 10.1016/j.trecan.2025.06.008. Online ahead of print.[Trends in Cancer PDF]
Nowicki, T.S.#, Deen, N.N.A., Peters, C.W., Comin-Anduix, B., Medina, E., Puig-Saus, C., Carretero, I.B., Kaplan-Lefko, P., Macabali, M.H., Garcilazo, I.P., Chen, D., Pang, J., Berent-Maoz, B., Haile, S., Rodriguez, J., Kawakami, M., Kidd, C.K., Champhekar, A., Carlucci, G., Vega-Crespo, A., Chmielowski, B., Singh, A., Federman, N., Schiller G.M., Larson, S.J., Allen-Auerbach, M., Klomhaus, A.M., Zack, J., Baltimore, D., Yang, L., Kohn, D.B., Witte, O.N., and Ribas, A. (#Corresponding author). Human cancer-targeted immunity via transgenic hematopoietic stem cell progeny. Nat Commun. 2025 Jul 1; 16:5599. doi.org/10.1038/s41467-025-60816-z. [Nature Communications PDF]
Li Y-R#, Zhu Y, and Yang L#. (#Co-corresponding authors). IL-15 in CAR engineering: striking an efficacy-safety balance. Trend Mol Med. 2025 Jun 18:S1471-4914(25)00137-6. doi: 10.1016/j.molmed.2025.05.014. Online ahead of print.[Trends in Molecular Medicine PDF]
Li B#, Elsten-Brown J, Li M, Zhu E, Li Z, Chen Y, Kang E, Ma F, Chiang J, Li Y-R, Zhu Y, Huang J, Fung A, Scarborough Q, Cadd R, Zhou JJ, Chin AI, Pellegrini M, and Yang L#. (#Co-corresponding authors). Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis. Cell. 2025 Jul 10;188(14):3823-3842.e21. doi: 10.1016/j.cell.2025.04.032. Epub 2025 May 21. [Cell PDF][UCLA Newsroom PDF][UCLA Health News PDF][UCLA BSCRC News PDF][Gizmodo PDF][Daily Mail PDF][Genetic Engineering & Biotechnology News PDF][Technology Networks PDF][Medpage Today PDF][Discover Magazine PDF][The Independent UK PDF][Yahoo PDF][OncoDaily PDF][Punjab News Express PDF][The Healthy Indian Project PDF][India New England News PDF][MDLinx PDF][Financial Express PDF][Earth.com PDF][Inside Precision Medicine PDF][Medical Dialogues PDF][Manchester Evening News PDF][MSN PDF]
Li Y-R*, Zhu Y*, Halladay T, and Yang L. (*Co-first authors). In vivo CAR engineering for immunotherapy. Nat Rev Immunol. 2025 May 16. doi: 10.1038/s41577-025-01174-1. Online ahead of print. [Nature Reviews Immunology PDF]
Li Y-R*#, Zhu Y*, Fang Y, Lyu Z, and Yang L#. (*Co-first authors; #Co-corresponding authors). Emerging trends in clinical allogeneic CAR cell therapy. Med. 2025 May 6:100677. doi: 10.1016/j.medj.2025.100677. Online ahead of print. [Med PDF]
Fang Y, Chen Y, Zhu Y, Tian Y, Li Y-R#, and Yang L#. (#Co-corresponding authors). Protocol to generate allorejection-resistant universal CAR-NKT cells and evaluate their efficacy, mechanism of action, safety, and immunogenicity. STAR Protoc. 2025 Jun 20;6(2):103810. doi: 10.1016/j.xpro.2025.103810. Epub 2025 May 2. [STAR Protocols PDF]
Lyu Z*, Niu S*, Fang Y, Chen Y, Li Y-R#, and Yang L#. (*Co-first authors; #Co-corresponding authors). Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer. Exp Hematol Oncol. 2025 May 2;14(1):66. doi: 10.1186/s40164-025-00654-3. [Experimental Hematology & Oncology PDF]
Cho JM, Vu K, Park S-K, Zhu E, Li Y-R, Zhao P, Yokota T, Yang L, Lu R, Xiang YK, Shen YH, Chapleau MW, and Hsiai TK. Habitual exercise modulates neuroimmune interaction to mitigate aortic stiffness. Circ Res. 2025 Jun 6;136(12):1579-1594. doi: 10.1161/CIRCRESAHA.124.325656. Epub 2025 Apr 30. [Circulation Research PDF]
Li Y-R*#, Shen X*, Zhu Y, Lyu Z, and Yang L# (*Co-first authors; #Co-corresponding authors). The microbiota shapes the life trajectory of mucosal-associated invariant T cells. Trends Microbiol. 2025 Apr 24:S0966-842X(25)00107-6. doi: 10.1016/j.tim.2025.03.011. Online ahead of print. [Trends in Microbiology PDF]
Li Y-R*, Ochoa CJ*, Lyu Z, Zhu Y, Chen Y, DiBernardo G, Ruegg L, Memarzadeh S# and Yang L#. (*Co-first authors; #Co-corresponding authors). Protocol to profile tumor and microenvironment from ovarian cancer patient samples and evaluate cell-based therapy using in vitro killing assays. STAR Protoc. 2025 Jun 20;6(2):103742. doi: 10.1016/j.xpro.2025.103742. Epub 2025 Apr 5. [STAR Protocols PDF]
Ruegg L, James-Allan LB, DiBernardo G, Ochoa C, Li Y-R, Yang L, and Memarzadeh S. An efficient method for extracting human fallopian tube epithelia for single-cell analyses. J Vis Exp. 2025 Mar 28:(217). doi: 10.3791/67753. [Jove PDF]
Li Y-R*#, Zhu Y*, Chen Y*, and Yang L#. (*Co-first authors; #Co-corresponding authors). The clinical landscape of CAR-engineered unconventional T cells. Trends Cancer. 2025 Jun;11(6):520-539. doi: 10.1016/j.trecan.2025.03.001. Epub 2025 Mar 27. [Trends in Cancer PDF]
Fang Y*, Chen Y*, Niu S, Lyu Z, Tian Y, Shen X, Li Y-R# & Yang L#. (*Co-first authors; #Co-corresponding authors). Biological functions and therapeutic applications of human mucosal-associated invariant T cells. J Biomed Sci. 2025 Mar 1; 32:32. doi: 10.1186/s12929-025-01125-x. [Journal of Biomedical Sciences PDF]
Li Y-R*, Fang Y*, Niu S*, Zhu Y*, Chen Y, Lyu Z, Zhu E, Tian Y, Huang J, Rezek V, Kitchen S, Hsiai T, Zhou JJ, Wang P, Chai-Ho W, Park S, Seet CS, Oliai C, and Yang L. (*Co-first authors). Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies. Nat Commun. 2025 Feb 1; 16(1):1248. doi: 10.1038/s41467-025-56270-6. [Nature Communications PDF][UCLA BSCRC PDF]
Li Y-R*, Zhou K*, Lee D*, Zhu Y, Halladay T, Yu J, Zhou Y, Lyu Z, Fang Y, Chen Y, Semaan S, and Yang L. (*Co-first authors). Generating allogeneic CAR-NKT cells for off-the-shelf cancer immunotherapy with genetically engineered HSP cells and feeder-free differentiation culture. Nat Protoc. 2025 May;20(5):1352-1388. doi: 10.1038/s41596-024-01077-w. Epub 2025 Jan 17. [Nature Protocols PDF]
Li Y-R*#, Lyu Z*, Shen X, Fang Y, and Yang L#. (*Co-first authors; #Co-corresponding authors). Boosting CAR-T cell Therapy through vaccine synergy. Trends Pharmacol Sci. 2025 Feb;46(2):180-199. doi: 10.1016/j.tips.2024.12.004. Epub 2025 Jan 3. [Trends in Pharmacological Sciences PDF]
Li Y-R*, Zhou K*, Zhu Y*, Halladay T*, and Yang L. (*Co-first authors). Breaking the mold: Unconventional T cells in cancer therapy. Cancer Cell. 2025 Mar 10;43(3):317-322. doi: 10.1016/j.ccell.2024.11.010. Epub 2024 Dec 12. [Cancer Cell PDF]
Li Y-R*#, Fang Y*, Niu S, Chen Y, Lyu Z, and Yang L#. (*Co-first authors; #Co-corresponding authors). Managing allorejection in off-the-shelf CAR-engineered cell therapies. Mol Ther. 2025 Jun 4;33(6):2368-2390. doi: 10.1016/j.ymthe.2024.11.035. Epub 2024 Nov 26. [Molecular Therapy PDF]
Liu Z*, Li Y-R*, Yang Y*, Zhu Y, Yuan W, Hoffman T, Wu Y, Zhu E, Zarubova J, Shen J, Nan H, Yeh K-W, Hasani-Sadrabadi MM, Zhu Y, Fang Y, Ge X, Li Z, Soto J, Hsiai T, Yang L# and Li S#. (*Co-first authors; #Co-corresponding authors). Viscoelastic synthetic antigen-presenting cells for augmenting the potency of cancer therapies. Nat. Biomed. Eng. 2024 Dec;8(12):1615-1633. doi: 10.1038/s41551-024-01272-w. Epub 2024 Oct 25. [Nature Biomedical Engineering PDF] [UCLA Samueli Newsroom PDF] [UCLA Health News PDF] [UCLA BSCRC News PDF]
Zhu E*, Yu J*, Li, Y-R, Ma F, Wang Y-C, Liu Y, Li M, Kim YJ, Zhu Y, Hahn Z, Zhou Y, Brown J, Zhang Y, Pellegrini M, Hsiai T, Yang L* and Huang Y#. (*Co-first authors; #Co-corresponding authors). Biomimetic cell stimulation with a graphene oxide antigen-presenting platform for developing T cell-based therapies. Nat. Nanotechnol. 2024 Dec;19(12):1914-1922. doi: 10.1038/s41565-024-01781-4. Epub 2024 Sep 23. [Nature Nanotechnology PDF][UCLA Life Sciences News PDF][UCLA Health News PDF][UCLA BSCRC News PDF][UCLA CNSI News PDF][AAAS EurekAlert! PDF]
Zhou K*, Sahakyan T*, Chen Y*, Halladay T, Dawson N, Semaan S, Guo F, Mendis A, Song A, Jazari MB, Ma T, Li Y-R# and Yang L#. (*Co-first authors; #Co-corresponding authors). Targeting tumor microenvironment for advanced cancer therapy. IntechOpen Book. 2024, September 18. DOI: 10.5772/intechopen.1004392. [IntechOpen PDF]
Zhu E, Li Y-R, Margolis S, Wang J, Wang K, Zhang Y, Wang S, Park J, Zheng C, Yang L, Chu A, Zhang Y, Gao L, and Hsiao TK. Frontiers in artificial intelligence-directed light-sheet microscopy for uncovering biological phenomena and multiorgan imaging. View. 2024, Sep 3. doi: 10.1002/VIW.20230087. [View PDF]
Li Y-R*#, Zibai Lyu*, Yuning Chen, Ying Fang, and Yang L#. (*Co-first authors; #Co-corresponding authors). Frontiers in CAR-T cell therapy for autoimmune diseases. Trends Pharmacol Sci. 2024 Sep;45(9):839-857. doi: 10.1016/j.tips.2024.07.005. Epub 2024 Aug 14. [Trends in Pharmacological Sciences PDF]
Li Y-R*, Zhou Y*, Yu J*, Kim YJ, Li M, Lee D, Zhou K, Chen Y, Zhu Y, Wang Y-C, Li Z, Yu Y, Dunn ZS, Guo W, Cen X, Husman T, Bajpai A, Kramer A, Wilson M, Fang Y, Huang J, Li S, Zhou Y, Zhang Y, Hahn Z, Zhu E, Ma F, Pan C, Lusis AJ, Zhou JJ, Seet CS, Kohn DB, Wang P, Zhou XJ, Pellegrini M, Puliafito BR, Larson SM, and Yang L. (*Co-first authors) Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method. Nat. Biotechnol. 2025 Mar; 43(3):329-344. doi: 10.1038/s41587-024-02226-y. Epub 2024 May 14. [Nature Biotechnology PDF][Nature Biotechnology News & Views PDF][Nature Portfolio PDF][UCLA Newsroom PDF][UCLA Health News PDF][UCLA BSCRC News PDF][Bioquick News PDF]
Li Y-R, Zhou Y, Yu J, Zhu Y, Lee D, Zhu E, Li Z, Kim YJ, Zhou K, Fang Y, Lyu Z, Zhen Y, Tian Y, Huang J, Cen X, Husman T, Cho JM, Hsiai T, Zhou JJ, Wang P, Puliafito BR, Larson SM, and Yang L. Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy. Mol Ther. 2024 Jun 5;32(6):1849-1874. doi: 10.1016/j.ymthe.2024.04.005. Epub 2024 Apr 6.[Molecular Therapy PDF]
Li Y-R*#, Halladay T*, and Yang L#. (*Co-first authors; #Co-Corresponding authors) Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies. J Biomed Sci. 2024, 31(1):5. doi: 10.1186/s12929-024-00998-8. [Journal of Biomedical Science PDF]
Lee D*, Dunn ZS*, Guo W*, Rosenthal CJ, Penn NE, Yu Y, Zhou K, Li Z, Ma F, Li M, Song T-C, Cen X, Li Y-R, Zhou JJ, Pellegrini M, Wang P, and Yang L. (*Co-first authors) Unlocking the potential of allogeneic Vδ2 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR/IL-15 engineering. Nat Commun. 2023, 14(1):6942. doi: 10.1038/s41467-023-42619-2. [Nature Communications PDF][UCLA News PDF][Springer Nature Blog PDF]
Li Y-R*, Ochoa CJ*, Zhu Y, Kramer A, Wilson M, Fang Y, Chen Y, Singh T, Di Bernardo G, Zhu E, Lee D, Moatamed NA, Bando J, Zhou JJ, Memarzadeh S#, and Yang L#. (*Co-first authors; #Co-corresponding authors) Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design. iScience. 2023, 26:107952. doi: 10.1016/j.isci.2023.107952. [iScience PDF][UCLA News PDF]
Wang S*, Cui Q*, Abiri P, Roustaei M, Zhu E, Li Y-R, Wang K, Duarte S, Yang L, Ebrahimi R, Bersohn M, Chen J, and Hsiai TK. (*Co-first authors) A self-assembled implantable microtubular pacemaker for wireless cardiac electrotherapy. Sci Adv. 2023, 9:eadj0540. doi: 10.1126/sciadv.adj0540. [Science Advances PDF]
Li Y-R#, Lyu Z, Tian Y, Fang Y, Zhu Y, Chen Y, and Yang L#. (#Co-corresponding authors) Advancements in CRISPR screens for the development of cancer immunotherapy strategies. Mol Ther Oncolytics. 2023, 31:100733. doi: 10.1016/j.omto.2023.100733. [Molecular Therapy Oncolytics PDF]
Li Y-R*#, Fang Y*, Lyu Z, Zhu Y, and Yang L#. (*Co-first authors; #Co-corresponding authors) Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies. J Transl Med. 2023, 21(1):686. doi: 10.1186/s12967-023-04575-9. [Journal of Translational Medicine PDF]
Zhu E*, Liu Y*, Huang J, Zhang A, Peng B, Liu Z, Liu H, Yu J, Li Y-R, Yang L, Duan X, and Huang Y. (*Co-first authors) Bubble-mediated large-scale hierarchical assembly of ultrathin Pt nanowire network monolayer at gas/liquid interfaces. ACS Nano. 2023, 17:14152-14160. doi: 10.1021/acsnano.3c04771.[ACS Nano PDF]
Chen Y*, Zhu Y*, Kramer A*, Fang Y, Wilson M, Li Y-R#, and Yang L#. (*Co-first authors; #Co-corresponding authors). Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapy. Front Med. 2023 Mar 29:10:1135468. doi: 10.3389/fmed.2023.1135468. eCollection 2023. [Frontiers in Medicine PDF]
Li Y-R*, Dunn ZS*, Yu Y, Li M, Wang P#, and Yang L#.(*Co-first authors; #Co-corresponding authors) Advancing cell-based cancer immunotherapy through stem cell engineering. Cell Stem Cell. 2023, 30(5):592-610. doi: 10.1016/j.stem.2023.02.009. [Cell Stem Cell PDF]
Li Y-R*, Zhou K*, Wilson M, Kramer A, Zhu Y, Dawson N, and Yang L. (*Co-first authors) Mucosal-associated invariant T cells for cancer immunotherapy. Mol Ther. 2023, Mar 1; 31(3):631-646. doi: 10.1016/j.ymthe.2022.11.019 doi: 10.1016/j.ymthe.2022.11.019. [Molecular Therapy PDF]
Fang Y*, Zhu Y*, Kramer A, Chen Y, Li Y-R#, and Yang L#.(*Co-first authors; #Co-corresponding authors) Graft-versus-host disease modulation by innate T cells. Int J Mol Sci. 2023, 24(4):4084. doi: 10.3390/ijms24044084. [International Journal of Molecular Sciences PDF]
Li Y-R*, Wilson M*, and Yang L. (*Co-first authors) Target tumor microenvironment by innate T cells. Front Immunol. 2022, 13:999549. doi: 10.3389/fimmu.2022.999549. [Frontiers in Immunology PDF]
Brown J, Li Z, Wang X, Kim YJ, Wang Y-C, Zuo Y, Hong W, Wang P, Li B*, and Yang L*. (*Co-corresponding authors) Nanoformulation improves antitumor efficacy of MAOI immune checkpoint blockade therapy without causing aggression-related side effects. Front Pharmacol. 2022, 13:970324. doi: 10.3389/fphar.2022.970324. [Frontiers in Pharmacology PDF]
Li Y-R*, Zeng S*, Dunn ZS, Zhou Y, Li Z, Yu J, Wang Y-C, Ku J, Cook N, Kramer A, and Yang L. (*Co-first authors) Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers. iScience. 2022, 25(9):104859. doi: 10.1016/j.isci.2022.104859. [iScience PDF][UCLA News PDF]
Li Y-R, Zhou Y, Wilson M, Kramer A, Hon R, Zhu Y, Fang Y, and Yang L. Tumor-localized administration of α-GalCer to recruit invariant natural killer T cells and enhance their antitumor activity against solid tumors. Int J Mol Sci. 2022, 23(14):7547. doi: 10.3390/ijms23147547. [International Journal of Molecular Sciences PDF]
Zhou Y*, Husman Tiffany*, Cen X, Tsao T, Brown J, Bajpai A, Li M, Zhou K, and Yang L. (*Co-first authors). Interleukin 15 in cell-based cancer immunotherapy. Int J Mol Sci. 2022, 23(13):7311. doi: 10.3390/ijms23137311. [International Journal of Molecular Sciences PDF]
Lee D, Rosenthal CJ, Penn NE, Dunn ZS, Zhou Y, and Yang L. Human γδ T cell subsets and their clinical applications for cancer immunotherapy. Cancers. 2022, 14(12):3035. doi: 10.3390/cancers14123005. [Cancers PDF]
Li Y-R, Brown J, Yu Y, Lee D, Zhou K, Dunn ZS, Hon R, Wilson M, Kramer A, Zhu Y, Fang Y, and Yang L. Targeting immunosuppressive tumor-associated macrophages using innate T cells for enhanced antitumor reactivity. Cancers. 2022, 14(11):2749. doi: 10.3390/cancers14112749. [Cancers PDF]
Li Y-R*, Yu Y*, Kramer A, Hon R, Wilson M, Brown J, and Yang L. (*Co-first authors). An ex vivo 3D tumor microenvironment-mimicry culture to study TAM modulation of cancer immunotherapy. Cells. 2022, 11(9):1583. doi: 10.3390/cells11091583. [Cells PDF]
Zhou Y*, Li M*, Zhou K*, Brown J, Tsao T, Cen X, Husman T, Baipai A, Dunn ZS, and Yang L. (*Co-first authors). Engineering induced pluripotent stem cells for cancer immunotherapy. Cancers. 2022, 14(9):2266. doi: 10.3390/cancers14092266. [Cancers PDF]
Yang L. Q&A. Cell Rep Med. 2022, 3:100616. doi: 10.1016/j.xcrm.2022.100616. [Cell Reports Medicine PDF]
Dunn ZS, Li Y-R, Yu Y, Lee D, Gibbons A, Kim JJ, Zhou TY, Li M, Nguyen M, Cen X, Zhou Y, Wang P, and Yang L. Minimally invasive preclinical monitoring of the peritoneal cavity tumor microenvironment. Cancers. 2022, 14(7):1775. doi: 10.3390/cancers14071775. [Cancers PDF]
Li Y-R, Dunn ZS, Garcia Jr. G, Carmona C, Zhou Y, Lee D, Yu J, Huang J, Kim JT, Arumugaswami V, Wang P, and Yang L. Development of off-the-shelf hematopoietic stem cell-engineered invariant natural killer T cells for COVID-19 therapeutic intervention. Stem Cell Res Ther. 2022, 13(1):112. doi: 10.1186/s13287-022-02787-2. [Stem Cell Research & Therapy PDF] [UCLA Blog PDF]
Brown J§, Li B§*, and Yang L*. (§Co-first authors; *Co-Corresponding authors). MAOI antidepressants: could they be a next-generation ICB therapy? Front Immunol. 2022, 13:853624. doi: 10.3389/fimmu.2022.853624. [Frontiers in Immunology PDF]
Nesterenko PA, McLaughlin J, Tsai BL, Sojo GB, Cheng D, Zhao D, Mao Z, Bangayan NJ, Obusan MB, Su Y, Ng RH, Chour W, Xie J, Li Y-R, Lee D, Noguchi M, Carmona C, Phillips JW, Kim JT, Yang L, Heath JR, Boutros PC, and Witte ON. HLA-A*02:01 restricted T cell receptors against the highly conserved SARS-CoV-2 polymerase cross-react with human coronaviruses. Cell Rep. 2021, 37(13):110167. doi: 10.1016/j.celrep.2021.110167. [Cell Reports PDF]
Li Y-R*, Dunn ZS*, Zhou Y, Lee D, and Yang L. (*Co-first authors). Development of Stem Cell-Derived Immune Cells for Off-the-Shelf Cancer Immunotherapies. Cells. 2021, 10(12):3497. doi: 10.3390/cells10123497. [Cells PDF]
Li Y-R, Zhou Y, Kramer A, and Yang L. Engineering stem cells for cancer immunotherapy. Trends Cancer. 2021, 7(12):1059-1073. doi: 10.1016/j.trecan.2021.08.004.
Li Y-R*, Zhou Y*, Kim Y, Zhu Y, Ma F, Yu J, Wang Y-C, Chen X, Li Z, Zeng S, Wang X, Lee D, Ku J, Tsao T, Hardoy C, Huang J, Cheng D, Montel-Hagen A, Seet CS, Crooks GM, Larson SM, Sasine JP, Wang X, Pellegrini M, Ribas A, Kohn DB, Witte O, Wang P, and Yang L. (*Co-first authors). Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy. Cell Rep Med. 2021, 2(11):100449. doi: 10.1016/j.xcrm.2021.100449. [Cell Reports Medicine PDF][UCLA News PDF][BSCRC News PDF][JCCC News PDF][Life Sciences News PDF][Science Daily PDF][CIRM Blog PDF]
Zhou Y, Li Y, Zeng S, and Yang L. Methods for studying mouse and human invariant natural killer T cells. Methods Mol Biol. 2021; 2388: 35-57. doi: 10.1007/978-1-0716-1775-5_4. [Methods in Molecular Biology PDF]
Wang Y-C, Wang X, Yu J, Ma F, Li Z, Zhou Y, Zeng S, Ma X, Li Y-R, Neal A, Huang J, To A, Clarke N, Memarzadeh S, Pellegrini M, and Yang L. Targeting monoamine oxidase A-regulated tumor-associated macrophage polarization for cancer immunotherapy. Nat Commun. 2021, 12:3530. doi: 10.1038/s41467-021-23164-2. [Nature Communications PDF][UCLA News PDF][CBS News PDF][NBC News PDF][Fierce Biotech News PDF][Drug Target Review News PDF]
Wang X, Li B, Kim Y, Wang Y, Li Z, Yu J, Zeng S, Ma X, Choi I, Di Biase S, Smith DJ, Zhou Y, Li Y, Ma F, Huang J, Clarke N, To A, Gong L, Pham A, Moon H, Pellegrini M, and Yang L. Targeting monoamine oxidase A for T cell-based cancer immunotherapy. Sci Immunol. 2021, 6:eabh2383. doi: 10.1126/sciimmunol.abh2383. [Science Immunology PDF][Science Magazine News PDF][UCLA News PDF][CBS News PDF][NBC News PDF][Fierce Biotech News PDF][Drug Target Review News PDF]
Li B* and Yang L*. (Co-corresponding authors). Creatine in T cell antitumor immunity and cancer immunotherapy. Nutrients. 2021, 13(5):1633. doi: 10.3390/nu13051633. [Nutrients PDF]
Li Z, Lee D, Zeng S, and Yang L. Successes and challenges of NKT cell immunotherapy: breaking tolerance to cancer resistance. In: Successes and Challenges of NK Immunotherapy. Academic Press: Elsevier. Book 2021, Pages 63-80. doi: 10.1016/B978-0-12-824375-6.00003-5. [Book Link][Chapter 4 Link PDF]
Di Biase S*, Ma X*, Wang X, Yu J, Wang Y-C, Smith DJ, Zhou Y, Li Z, Kim YJ, Clarke N, To A, and Yang L. (*Co-first authors). Creatine uptake regulates CD8 T cell antitumor immunity. J Exp Med. 2019, 216(12): 2869-2882. doi: 10.1084/jem.20182044. [JEM PDF][UCLA News PDF][UC News PDF][MedicalXpress PDF][ScienceDaily PDF][The Medical News PDF][Technology Networks PDF]
Zhu Y*, Smith DJ*, Zhou Y, Li YR, Yu J, Lee D, Wang Y-C, Di Biase S, Wang Xi, Hardoy C, Ku J, Tsao T, Lin LJ, Pham AT, Moon H, McLaughlin J, Cheng D, Hollis RP, Campo-Fernandez B, Urbinati F, Wei L, Pang L, Rezek V, Berent-Maoz B, Macabali MH, Gjertson D, Wang X, Galic Z, Kitchen SG, An DS, Hu-Lieskovan S, Kaplan-Lefko PJ, De Oliveira SN, Seet CS, Larson SM, Forman SJ, Heath JR, Zack JA, Crooks GM, Radu GR, Ribas A, Kohn DB, Witte ON, and Yang L. (*Co-first authors). Development of hematopoietic stem cell-engineered invariant natural killer T cell therapy for cancer. Cell Stem Cell. 2019, 25(4):542-557. doi: 10.1016/j.stem.2019.08.004. [Cell Stem Cell PDF][CSC Highlight PDF][UCLA BSCRC News PDF][UCLA Health News PDF][Medical News Today PDF][SciTechDaily PDF][The Stem Cell Podcast PDF]
Puig-Saus C, Parisi G, Garcia-Diaz A, Krystofinski PE, Sandoval S, Zhang R, Champhekar AS, McCabe J, Cheung-Lau GC, Truong NA, Vega-Crespo A, Komenan MDS, Pang J, Macabali MH, Saco JD, Goodwin JL, Bolon B, Seet CS, Montel-Hagen A, Crooks GM, Hollis RP, Campo-Fernandez B, Bischof D, Cornetta K, Gschweng EH, Adelson C, Nguyen A, Yang L, Witte ON, Baltimore D, Comin-Anduix B, Kohn DB, Wang X, Cabrera P, Kaplan-Lefko PJ, Berent-Maoz B, and Ribas A. IND-enabling studies for a clinical trial to genetically program a persistent cancer-targeted immune system. Clin Cancer Res. 2019, 25(3):1000-1011. doi: 10.1158/1078-0432.CCR-18-0963. [Clinical Cancer Research PDF]
Bethune MT§, Li XH§, Yu J§, McLaughlin J, Cheng D, Mathis C, Moreno BH, Woods K, Knights AJ, Garcia-Diaz A, Wong S, Hu-Lieskovan S, Saus CP, Cebon J, Ribas A, Yang L*, Witte ON*, and Baltimore D*. (§Co-first authors; *Co-corresponding authors). Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules. Proc Natl Acad Sci U S A. 2018, 115(45): E107002-E10711. doi: 10.1073/pnas.1810653115. [PNAS PDF]
Siegler EL, Zhu Y, Wang P*, and Yang L*. (*Co-corresponding authors). Off-the-shelf CAR-NK cells for cancer immunotherapy. Cell Stem Cell. 2018, 23(8):160-161. doi: 10.1016/j.stem.2018.07.007. [Cell Stem Cell PDF]
Nowicki TS, Escuin-Ordinas H, Avramis E, Chmielowski B, Chodon T, Berent-Maoz B, Wang X, Kaplan-Lefko P, Yang L, Baltimore D, Economou JS, Ribas A, and Comin-Anduix B. Characterization of postinfusion phenotypic differences in fresh versus cryopreserved TCR engineered adoptive cell therapy products. J Immunother. 2018, 41(5):248-259. doi: 10.1097/CJI.0000000000000216. [Journal of Immunotherapy PDF]
Li B*, Wang X*, Choi I, Liu S, Pham A, Moon H, Rao DS, Boldin MP, and Yang L. (*Co-first authors). miR-146a modulates autoreactive CD4 T cell Th17 differentiation and regulates T cell-mediated autoimmunity. J Clin Invest. 2017, 127(10):3702-3716. doi: 10.1172/JCI94012. [Journal of Clinical Investigation PDF]
Kim JT, Liu Y, Kulkarni RP, Lee KK, Dai BB, Lovely G, Ouyang Y, Wang P, Yang L, and Baltimore D. Dendritic cell-targeted lentiviral vector immunization uses pseudotransduction and DNA-mediated STING and cGAS activation. Sci Immunol. 2017, 2:eaal1329. doi: 10.1126/sciimmunol.aal1329. [Science Immunology PDF]
Smith DJ, Lin LJ, Moon H, Pham AT, Wang X, Liu S, Ji S, Rezek V, Shimizu S, Ruiz M, Lam J, Janzen DM, Memarzadeh S, Kohn DB, Zack JA, Kitchen SG, An DS, and Yang L. Propagating humanized BLT mice for the study of human immunology and immunotherapy. Stem Cells Dev. 2016, 25(24):1863-1873. doi: 10.1089/scd.2016.0193. [Stem Cells and Development PDF]
Smith DJ, Liu S, Ji S, Li B, McLaughlin J, Cheng D, Witte ON, and Yang L. Genetic Engineering of hematopoietic stem cells to generate invariant natural killer T cells. Proc Natl Acad Sci U S A. 2015, 112(5):1523-1528. doi: 10.1073/pnas.1424877112. [PNAS PDF][Hematopoiesis News TOP STORY]
Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, Gjertson DW, Cochran AJ, Cornetta K, Wong DJL, Kaplan-Lefko P, Hamid O, Samlowski W, Cohen PA, Daniels GA, Mukherji B, Yang L, Zack JA, Kohn DB, Heath JR, Glaspy JA, Witte ON, Baltimore D, Economou JS, and Ribas A. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res. 2014, 20(9): 2457-2465. doi: 10.1158/1078-0432.CCR-13-3017. [Clinical Cancer Research PDF]
Yang L* and Wang P. (*Co-corresponding author). Passive immunization against HIV/AIDS by antibody gene transfer. Viruses. 2014, 6(2): 428-447. doi: 10.3390/v6020428. [Viruses PDF]
Hur EM, Patel SN, Shimizu S, Rao D, Gnanapragasam PNP, An DS, Yang L*, and Baltimore D*. (*Co-corresponding authors). Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice. Blood. 2012, 120(23): 4571-4582. doi: 10.1182/blood-2012-04-422303. [Blood PDF]
Yu KK, Aguilar K, Tsai J, Galimidi R, Gnanapragasam P, Yang L, and Baltimore D. Use of mutated self-cleaving 2A peptides as a molecular rheostat to direct simultaneous formation of membrane and secreted anti-HIV immunoglobulins. PLoS One. 2012, 7(11):e50438. doi: 10.1371/journal.pone.0050438. [PLoS One PDF]
Yang L*, Boldin MP, Yu Y, Liu CS, Ea CK, Taganov KD, Zhao JL, and Baltimore D*. (*Co-corresponding authors). miR-146a controls the resolution of T cell responses in mice. J Exp Med. 2012, 209(9): 1655-1670. doi: 10.1084/jem.20112218. [Journal of Experimental Medicine PDF]
Xiao L, Kim J, Lim M, Dai B, Yang L, Reed S, Baltimore D, and Wang P. A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses. Vaccine. 2012, 30(15): 2570-2581. doi: 10.1016/j.vaccine.2012.01.074. [Vaccine PDF]
Balazs AB, Chen J, Hong CM, Rao DS, Yang L, and Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature. 2011, 481(7379): 81-84. doi: 10.1038/nature10660. [Nature PDF]
Yang L*, Yu Y, Kalwani M, Tseng TW, and Baltimore D*. (*Co-corresponding authors). Homeostatic cytokines orchestrate the segregation of CD4 and CD8 memory T-cell reservoirs in mice. Blood. 2011, 118(11): 3039-3050. doi: 10.1182/blood-2011-04- 349746. [Blood PDF]
Boldin MP, Taganov KD, Rao DS, Yang L, Zhao JL, Kalwani M, Garcia-Flores Y, Luong M, Devrekanli A, Xu J, Sun G, Tay J, Linsley PS, and Baltimore D. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med. 2011, 208(6): 1189-1201. doi: 10.1084/jem.20101823. [Journal of Experimental Medicine PDF]
Luo XM, Lei MY, Feidi RA, West AP Jr, Balazs AB, Bjorkman PJ, Yang L*, and Baltimore D*. (*Co-corresponding authors). Dimeric 2G12 as a potent protection against HIV-1. PLoS Pathog. 2010, 6(12): e1001225. doi: 10.1371/journal.ppat.1001225. [PLoS Pathogens PDF]
O’Connell RM, Balazs AB, Rao DS, Kivork C, Yang L*, and Baltimore D*. (*Co-corresponding authors). Lentiviral vector delivery of human interleukin-7 (hIL-7) to human immune system (HIS) mice expands T lymphocyte populations. PLoS One. 2010, 5(8): e12009. doi: 10.1371/journal.pone.0012009. [PLoS One PDF]
Baltimore D, Witte ON, Yang L, Economou J, and Ribas A. Overcoming barriers to programming a therapeutic cellular immune response to fight melanoma. Pigment Cell Melanoma Res. 2010, 23(2): 288-289. doi: 10.1111/j.1755-148X.2010.00666.x. [Pigment Cell & Melanoma Research PDF]
Dai B, Yang L, Yang H, Hu B, Baltimore D, and Wang P. HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells. Proc Natl Acad Sci U S A. 2009, 106(48): 20382-20387. doi: 10.1073/pnas.0911742106. [PNAS PDF]
Luo XM, Maarschalk E, O’Connell RM, Wang P, Yang L*, and Baltimore D*. (*Co-corresponding authors). Engineering human hematopoietic stem/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes. Blood. 2009, 113(7): 1422-1431. doi: 10.1182/blood-2008-09-177139. [Blood PDF]
Ziegler L, Yang L, Joo Ki, Yang H, Baltimore D, and Wang P. Targeting lentiviral vectors to antigen-specific immunoglobulins. Hum Gene Ther. 2008, 19(9): 861-872. doi: 10.1089/hum.2007.149. [Human Gene Therapy PDF]
Chhabra A, Yang L, Wang P, Comin-Anduix B, Das R, Chakraborty NG, Ray S, Mehrotra S, Yang H, Hardee CL, Hollis R, Dorsky DI, Koya R, Kohn DB, Ribas A, Economou JS, Baltimore D, and Mukherji B. CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model. J Immunol. 2008, 181(2): 1063-1070. doi: 10.4049/jimmunol.181.2.1063. [Journal of Immunology PDF]
Yang L*, Yang H*, Rideout K, Cho T, Joo KI, Ziegler L, Elliot A, Walls A, Yu D, Baltimore D§, and Wang P§. (*Co-first authors; §Co-corresponding authors). Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol. 2008, 26(3): 326-334. doi: 10.1038/nbt1390. [Nature Biotechnology PDF]
Yang L, Bailey L, Baltimore D*, and Wang P*. (*Co-corresponding authors). Targeting lentiviral vectors to specific cell types in vivo. Proc Natl Acad Sci U S A. 2006, 103(31): 11479-11484. doi: 10.1073/pnas.0604993103. [PNAS PDF]
Yang L and Baltimore D. Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells. Proc Natl Acad Sci U S A. 2005, 102(12): 4518-4523. doi: 10.1073/pnas.0500600102. [PNAS PDF]
Bridges R, Rigero B, Byrnes E, Yang L, and Walker A. Central infusions of the recombinant human prolactin receptor antagonist, S179D-PRL, delay the onset of maternal behavior in steroid-primed, nulliparous female rats. Endocrinology. 2001, 142(2): 730-739. doi: 10.1210/endo.142.2.7931. [Endocrinology PDF]
Yang L, Kuo CB, Liu Y, Coss D, Xu X, Chen C, Oster-Granite ML, and Walker AM. Administration of unmodified prolactin (U-PRL) and a molecular mimic of phosphorylated prolactin (PP-PRL) during rat pregnancy provides evidence that the U-PRL:PP-PRL ratio is crucial to the normal development of pup tissues. J Endocrinol. 2001, 168(2): 227-238. doi: 10.1677/joe.0.1680227. [Journal of Endocrinology PDF]
Coss D, Yang L, Kuo CB, Xu X, Luben RA, and Walker AM. Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat. Am J Physiol Endocrinol Metab. 2000, 279(6): E1216-E1225. doi: 10.1152/ajpendo.2000.279.6.E1216. [Endocrinology and Metabolism PDF]
Coss D, Kuo CB, Yang L, Ingleton P, Luben R, and Walker AM. Dissociation of Janus kinase 2 and signal transducer and activator of transcription 5 activation after treatment of Nb2 cells with a molecular mimic of phosphorylated prolactin. Endocrinology. 1999, 140(11): 5087-5094. doi: 10.1210/endo.140.11.7104. [Endocrinology PDF]